AGP Konstas, CH Karabatsas, N Lallos, N Georgiadis, … - Ophthalmology, 2005 - Elsevier Subjects were randomized to brimonidine purite or dorzolamide, each given twice daily, for the
first 6-week treatment period after a 6-week latanoprost run-in. Subjects began the opposite treatment
for the second 6-week period after a 6-week latanoprost-only treatment between periods. ... Cited by 19 - Related articles - All 13 versions
RM Feldman, AP Tanna, RL Gross, AZ Chuang, L … - Ophthalmology, 2007 - Elsevier Presented in part at: American Glaucoma Society Annual Meeting, March 2006, Charleston,
South Carolina, and Association for Research and Vision in Ophthalmology Annual Meeting,
April 2006, Fort Lauderdale, Florida. ... 1 Department of Ophthalmology and Visual ... Cited by 13 - Related articles - All 16 versions
ES Arcieri, RS Arcieri, ACA Pereira, EGV … - Current Medical …, 2007 - informahealthcare.com Enyr s. Arcieria,b, Rafael s. Arcierib, Ana CA pereirac, Eduardo GV Andreob, ioná GA Finottib
and Wanderley F. sá Filhob ... Address for correspondence: Enyr S. Arcieri, MD, Department
of Ophthalmology, School of Medicine, Federal University of Uberlândia, Rua Corcovado, ... Cited by 6 - Related articles - BL Direct - All 6 versions
LB Cantor - Therapeutics and Clinical Risk Management, 2006 - pubmedcentral.nih.gov Treatment in glaucoma aims to lower intraocular pressure (IOP) to reduce the risk of progression
and vision loss. The alpha2-adrenergic receptor agonist brimonidine effectively lowers IOP and
is useful as monotherapy, adjunctive therapy, and replacement therapy in open-angle ... Cited by 5 - Related articles - BL Direct - All 7 versions
DG Day, DA Hollander - Current Medical Research and Opinion …, 2008 - informahealthcare.com Objective: To evaluate the efficacy and tolerability of brimonidine purite 0.1% in comparison to
brinzolamide 1% when used as adjunctive therapy to latanoprost 0.005% in patients with glaucoma
or ocular hypertension. Methods: Randomized, single-center, investigator-masked, ... Cited by 4 - Related articles - All 5 versions
L Jay Katz, ST Simmons, E Randy … - … Medical Research and …, 2007 - informahealthcare.com L. Jay Katz a, Steven T. Simmons b and e. Randy Craven c ... Address for correspondence:
L. Jay Katz, MD, Glaucoma Wills Eye Hospital, 840 Walnut St, Ste 1110, Philadelphia, PA
19107, USA. Tel.: +1 215 928 3197; Fax: +1 215 928 0166; ljkatz@willseye.org Key ... Cited by 2 - Related articles - BL Direct - All 4 versions
A Galanopoulos, I Goldberg - 2009 - pubmedcentral.nih.gov Elevated intraocular pressure (IOP) is a significant risk factor for the development and progression
of glaucomatous optic neuropathy, but increasingly we appreciate that non-pressure dependent
factors, are key to our understanding of the pathophysiology of these neurodegenerative ... Related articles - All 5 versions
W PDLAC - uwacadweb.uwyo.edu This publication is a result of the collaboration of the Goold Health Systems, Inc. Clinical Workgroup
and represents the opinion of these authors based on a review of the literature available at the
time it was written. It is intended for the sole purpose of providing information to committee ... Related articles
